Braco-19 NEW
| Price | $48 | $113 | $189 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-17 |
Product Details
| Product Name: Braco-19 | CAS No.: 351351-75-2 |
| Purity: 97.01% | Supply Ability: 10g |
| Release date: 2024/11/17 |
Product Introduction
Bioactivity
| 名稱 | Braco-19 |
| 描述 | Braco-19 is a telomerase/telomere inhibitor and an inhibitor of HAdV viral replication with antiviral activity that reduces lipid vacuolization in adipocytes, inhibits proliferation and decreases telomerase activity in human glioblastoma cells. |
| 體外活性 | At 1 μM, the growth inhibitory effect of BRACO-19 (1.0-10 μM; 5 days) was null, the IC50 of BRACO-19 in UXF1138L cells was 2.5 μM, the IC100 was 5 μM, and BRACO-19 (1 μM; 24 h) significantly reduced the expression of hTERT in the nucleus. In eGFP-transfected HEK 293 cells, BRACO-19 (0-40 μM; 24 h) reduced the growth of AdV viruses in a dose-dependent manner [5]; BRACO-19 (0-150 μM; 24 h) reduced the band intensity in a concentration-dependent increase; and BRACO-19 interacted specifically with the HAdV GQ, increasing its stability and blocking the propagation of HAdV [6]. |
| 體內(nèi)活性 | BRACO-19 (intraperitoneal injection; 2 mg/kg; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments) inhibits tumor growth significantly and under these conditions, marked single-agent antitumor activity is observed, with some animals in the group showing complete regressions (5 of 12 tumors)[5]. BRACO-19 (oral administration or intraperitoneal injection; 2 or 5 mg/kg; 3 weeks) oral dosing regimen are always inactive and the animals have to be sacrificed due to high tumor burden before overall termination of the study, Chronic, i.p. BRACO-19 administration, qdx5 is efficient in inhibiting tumor growth in earlystage xenografts but not advanced-stage xenografts[5]. |
| 存儲條件 | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 20 mg/mL (33.68 mM), Sonication is recommended. |
| 關(guān)鍵字 | Braco19 | Braco-19 | Braco 19 |
| 相關(guān)產(chǎn)品 | BTA-188 | 2,2'-Anhydrouridine | Oxytetracycline Hydrochloride | Costunolide | Rociclovir PM | Valganciclovir hydrochloride | Moroxydine hydrochloride | Arbidol | 3-Methoxycatechol | Ceramides Mixture |
| 相關(guān)庫 | 經(jīng)典已知活性庫 | 抗衰老化合物庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $58.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-13 | |
| $1.00/1KG |
VIP2Y
|
Jinan Million Pharmaceutical Co., Ltd
|
2023-12-18 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY